P

Plus Therapeutics
D

PSTV

1.20000
USD
-0.09
(-6.98%)
مغلق
حجم التداول
581
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
7,075,600
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    AMC
    -0.06100
    (-1.75%)
    3.43000 USD
    CMCSA
    CMCSA
    -0.155
    (-0.43%)
    36.250 USD
    C
    CNK
    -0.370
    (-1.33%)
    27.440 USD
    DIS
    DIS
    -1.910
    (-1.73%)
    108.670 USD
    F
    FOXA
    -0.430
    (-0.75%)
    56.960 USD
    I
    IMAX
    -0.890
    (-3.31%)
    26.020 USD
    NFLX
    NFLX
    -22.12
    (-2.16%)
    1,002.42 USD
    T
    T
    0.480
    (1.83%)
    26.640 USD
    المزيد
الأخبار
المقالات

العنوان: Plus Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).